Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

Y. Tanaka, Tsutomu Takeuchi, T. Mimori, K. Saito, M. Nawata, H. Kameda, T. Nojima, N. Miyasaka, T. Koike

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Background: Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons. Objective: To determine whether infliximab might be discontinued after achievement of LDA in patients with RA and to evaluate progression of articular destruction during the discontinuation. Methods: 114 patients with RA who had received infliximab treatment, and whose Disease Activity Score, including a 28-joint count (DAS28) was <3.2 (LDA) for 24 weeks, were studied. Results: The mean disease duration of the 114 patients was 5.9 years, mean DAS28 5.5 and mean modified total Sharp score (mTSS) 63.3. After maintaining LDA for >24 weeks by infliximab treatment, the drug was discontinued and DAS28 in 102 patients was evaluated at year 1. Fifty-six patients (55%) continued to have DAS28<3.2 and 43% reached DAS<2.6 at 1 year after discontinuing infliximab. For 46 patients remission induction by Remicade in RA (RRR) failed: disease in 29 patients flared within 1 year and DAS28 was >3.2 at year 1 in 17 patients. Yearly progression of mTSS (ΔTSS) remained <0.5 in 67% and 44% of the RRR-achieved and RRR-failed groups, respectively. The estimated ΔmTSS was 0.3 and 1.6 and Health Assessment Questionnaire-Disability Index was 0.174 and 0.614 in the RRR-achieved and RRR-failed groups, respectively, 1 year after the discontinuation. Conclusion: After attaining LDA by infliximab, 56 (55%) of the 102 patients with RA were able to discontinue infliximab for >1 year without progression of radiological articular destruction.

Original languageEnglish
Pages (from-to)1286-1291
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume69
Issue number7
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Remission Induction
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Joints
Economics
Infliximab
Pharmaceutical Preparations
Safety
Therapeutics

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. / Tanaka, Y.; Takeuchi, Tsutomu; Mimori, T.; Saito, K.; Nawata, M.; Kameda, H.; Nojima, T.; Miyasaka, N.; Koike, T.

In: Annals of the Rheumatic Diseases, Vol. 69, No. 7, 07.2010, p. 1286-1291.

Research output: Contribution to journalArticle

Tanaka, Y. ; Takeuchi, Tsutomu ; Mimori, T. ; Saito, K. ; Nawata, M. ; Kameda, H. ; Nojima, T. ; Miyasaka, N. ; Koike, T. / Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis : RRR (remission induction by Remicade in RA) study. In: Annals of the Rheumatic Diseases. 2010 ; Vol. 69, No. 7. pp. 1286-1291.
@article{567f8ba909c345f7806ac2eee3203755,
title = "Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study",
abstract = "Background: Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons. Objective: To determine whether infliximab might be discontinued after achievement of LDA in patients with RA and to evaluate progression of articular destruction during the discontinuation. Methods: 114 patients with RA who had received infliximab treatment, and whose Disease Activity Score, including a 28-joint count (DAS28) was <3.2 (LDA) for 24 weeks, were studied. Results: The mean disease duration of the 114 patients was 5.9 years, mean DAS28 5.5 and mean modified total Sharp score (mTSS) 63.3. After maintaining LDA for >24 weeks by infliximab treatment, the drug was discontinued and DAS28 in 102 patients was evaluated at year 1. Fifty-six patients (55{\%}) continued to have DAS28<3.2 and 43{\%} reached DAS<2.6 at 1 year after discontinuing infliximab. For 46 patients remission induction by Remicade in RA (RRR) failed: disease in 29 patients flared within 1 year and DAS28 was >3.2 at year 1 in 17 patients. Yearly progression of mTSS (ΔTSS) remained <0.5 in 67{\%} and 44{\%} of the RRR-achieved and RRR-failed groups, respectively. The estimated ΔmTSS was 0.3 and 1.6 and Health Assessment Questionnaire-Disability Index was 0.174 and 0.614 in the RRR-achieved and RRR-failed groups, respectively, 1 year after the discontinuation. Conclusion: After attaining LDA by infliximab, 56 (55{\%}) of the 102 patients with RA were able to discontinue infliximab for >1 year without progression of radiological articular destruction.",
author = "Y. Tanaka and Tsutomu Takeuchi and T. Mimori and K. Saito and M. Nawata and H. Kameda and T. Nojima and N. Miyasaka and T. Koike",
year = "2010",
month = "7",
doi = "10.1136/ard.2009.121491",
language = "English",
volume = "69",
pages = "1286--1291",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis

T2 - RRR (remission induction by Remicade in RA) study

AU - Tanaka, Y.

AU - Takeuchi, Tsutomu

AU - Mimori, T.

AU - Saito, K.

AU - Nawata, M.

AU - Kameda, H.

AU - Nojima, T.

AU - Miyasaka, N.

AU - Koike, T.

PY - 2010/7

Y1 - 2010/7

N2 - Background: Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons. Objective: To determine whether infliximab might be discontinued after achievement of LDA in patients with RA and to evaluate progression of articular destruction during the discontinuation. Methods: 114 patients with RA who had received infliximab treatment, and whose Disease Activity Score, including a 28-joint count (DAS28) was <3.2 (LDA) for 24 weeks, were studied. Results: The mean disease duration of the 114 patients was 5.9 years, mean DAS28 5.5 and mean modified total Sharp score (mTSS) 63.3. After maintaining LDA for >24 weeks by infliximab treatment, the drug was discontinued and DAS28 in 102 patients was evaluated at year 1. Fifty-six patients (55%) continued to have DAS28<3.2 and 43% reached DAS<2.6 at 1 year after discontinuing infliximab. For 46 patients remission induction by Remicade in RA (RRR) failed: disease in 29 patients flared within 1 year and DAS28 was >3.2 at year 1 in 17 patients. Yearly progression of mTSS (ΔTSS) remained <0.5 in 67% and 44% of the RRR-achieved and RRR-failed groups, respectively. The estimated ΔmTSS was 0.3 and 1.6 and Health Assessment Questionnaire-Disability Index was 0.174 and 0.614 in the RRR-achieved and RRR-failed groups, respectively, 1 year after the discontinuation. Conclusion: After attaining LDA by infliximab, 56 (55%) of the 102 patients with RA were able to discontinue infliximab for >1 year without progression of radiological articular destruction.

AB - Background: Tumour necrosis factor (TNF) inhibitors enable tight control of disease activity in patients with rheumatoid arthritis (RA). Discontinuation of TNF inhibitors after acquisition of low disease activity (LDA) is important for safety and economic reasons. Objective: To determine whether infliximab might be discontinued after achievement of LDA in patients with RA and to evaluate progression of articular destruction during the discontinuation. Methods: 114 patients with RA who had received infliximab treatment, and whose Disease Activity Score, including a 28-joint count (DAS28) was <3.2 (LDA) for 24 weeks, were studied. Results: The mean disease duration of the 114 patients was 5.9 years, mean DAS28 5.5 and mean modified total Sharp score (mTSS) 63.3. After maintaining LDA for >24 weeks by infliximab treatment, the drug was discontinued and DAS28 in 102 patients was evaluated at year 1. Fifty-six patients (55%) continued to have DAS28<3.2 and 43% reached DAS<2.6 at 1 year after discontinuing infliximab. For 46 patients remission induction by Remicade in RA (RRR) failed: disease in 29 patients flared within 1 year and DAS28 was >3.2 at year 1 in 17 patients. Yearly progression of mTSS (ΔTSS) remained <0.5 in 67% and 44% of the RRR-achieved and RRR-failed groups, respectively. The estimated ΔmTSS was 0.3 and 1.6 and Health Assessment Questionnaire-Disability Index was 0.174 and 0.614 in the RRR-achieved and RRR-failed groups, respectively, 1 year after the discontinuation. Conclusion: After attaining LDA by infliximab, 56 (55%) of the 102 patients with RA were able to discontinue infliximab for >1 year without progression of radiological articular destruction.

UR - http://www.scopus.com/inward/record.url?scp=77954973766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954973766&partnerID=8YFLogxK

U2 - 10.1136/ard.2009.121491

DO - 10.1136/ard.2009.121491

M3 - Article

C2 - 20360136

AN - SCOPUS:77954973766

VL - 69

SP - 1286

EP - 1291

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 7

ER -